Tumor cell plasticity in targeted therapy-induced resistance: mechanisms and new strategies
Open accessThe DOI matches its Crossref record; 374 of the 374 references it cites were found in a registry or an index.
Abstract
Despite the success of targeted therapies in cancer treatment, therapy-induced resistance remains a major obstacle to a complete cure. Tumor cells evade treatments and relapse via phenotypic switching driven by intrinsic or induced cell plasticity. Several reversible mechanisms have been proposed to circumvent tumor cell plasticity, including epigenetic modifications, regulation of transcription factors, activation or suppression of key signaling pathways, as well as modification of the tumor environment. Epithelial-to-mesenchymal transition, tumor cell and cancer stem cell formation also serve as roads towards tumor cell plasticity. Corresponding treatment strategies have recently been developed that either target plasticity-related mechanisms or employ combination treatments. In this review, we delineate the formation of tumor cell plasticity and its manipulation of tumor evasion from targeted therapy. We discuss the non-genetic mechanisms of targeted drug-induced tumor cell plasticity in various types of tumors and provide insights into the contribution of tumor cell plasticity to acquired drug resistance. New therapeutic strategies such as inhibition or reversal of tumor cell plasticity are also presented. We also discuss the multitude of clinical trials that are ongoing worldwide with the intention of improving clinical outcomes. These advances provide a direction for developing novel therapeutic strategies and combination therapy regimens that target tumor cell plasticity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Induction can be achieved with ketamine or AMPA-potentiating ampakines of the CX series, which rapidly boost Ca2+-permeable AMPAR drive, elevate BDNF, and engage mTOR-ERK pathways while sparing Hebbian learning capacity [341,342].”
From Synaptic Plasticity—Intrinsic Excitability and Antidepressant Discovery (2026) · cites this paper as [342]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“In chronic stress paradigms, (R)-ketamine co-administered with LY341495, a selective group II mGlu2/3 antagonist, yields rapid and long-lasting behavioral improvement through BDNF-TrkB and AMPAR mechanisms, with synaptogenesis that outlasts single-agent effects [342,345].”
From Synaptic Plasticity—Intrinsic Excitability and Antidepressant Discovery (2026) · cites this paper as [342]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Zeng, D., Liang, Y., Xiao, Y., Wei, X., Lin, H., Wu, Y., Bai, J., Chen, M., & Zhang, G. (2020) · International Journal of Cancer · doi:10.1002/ijc.32911 · Cited by 71
RetractedmiRNA‑490‑3p promotes the metastatic progression of invasive ductal carcinoma
Lü, N., Zhang, M., Lu, L., Liu, Y., Zhang, H., & Liu, X. (2020) · Oncology Reports · doi:10.3892/or.2020.7880 · Cited by 10 · cited 1×
“Other newly identified EMT-related miRNAs include miR-27b3p,(206) which promotes the generation of circulating tumor cells, and miRNA-490-3p, which promotes the metastasis of invasive ductal carcinoma.(207) Nonetheless, recent studies have reported that some miRNAs, such as miRNA-128 MiRNA-155-5p,(208,209) are able to…”
BackgroundRetractedInduction of Pluripotent Stem Cells from Adult Human Fibroblasts by Defined Factors
Takahashi, K., Tanabe, K., Ohnuki, M., Narita, M., Ichisaka, T., Tomoda, K., & Yamanaka, S. (2007) · Cell · doi:10.1016/j.cell.2007.11.019 · Cited by 20,221
Shrestha, S., & Offer, S. M. (2016) · Medical Epigenetics · doi:10.1159/000444713 · Cited by 8,914
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
Wolchok, J. D., Chiarion-Sileni, V., Gonzalez, R., Rutkowski, P., Grob, J.-J., Cowey, C. L., Lao, C. D., Wagstaff, J., Schadendorf, D., Ferrucci, P. F., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709684 · Cited by 5,357
Accessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment
Hanahan, D., & Coussens, L. M. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.02.022 · Cited by 4,632
Kalluri, R., & Zeisberg, M. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1877 · Cited by 4,538
Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer
Schmid, P., Adams, S., Rugo, H. S., Schneeweiss, A., Barrios, C. H., Iwata, H., Diéras, V., Hegg, R., Im, S.-A., Shaw Wright, G., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1809615 · Cited by 4,350
Twist, a Master Regulator of Morphogenesis, Plays an Essential Role in Tumor Metastasis
Yang, J., Mani, S. A., Donaher, J. L., Ramaswamy, S., Itzykson, R. A., Come, C., Savagner, P., Gitelman, I., Richardson, A., & Weinberg, R. A. (2004) · Cell · doi:10.1016/j.cell.2004.06.006 · Cited by 3,855
Tumour heterogeneity and resistance to cancer therapies
Dagogo-Jack, I., & Shaw, A. T. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.166 · Cited by 3,846 · cited 1×
“Heterogeneity may lead to divergent sensitivity to treatment and facilitate the development of drug resistance.(210) The most recent tumor heterogeneity model is known as the CSC plasticity model.”
Background
Research works printed but not linked: 1
- Yingling, J. M. et al. Preclinical assessment of galunisertib (LY2157299 monohydrate), a first-in-class transforming growth factor-beta receptor type I inhibitor. Oncotarget 9, 6659–6677 (2018). · DOI · Paper page
Cited by
Unveiling the mechanisms and challenges of cancer drug resistance
Khan, S. U., Fatima, K., Aisha, S., & Malik, F. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-023-01302-1 · Cited by 417
“Cancer cells follow the Darwinian selection pressure rule to achieve drug-resistant traits at genomic, epigenomic and proteomic levels for the survival of their fittest [37– 39].”
BackgroundInvasion and metastasis in cancer: molecular insights and therapeutic targets
Li, Y., Liu, F., Cai, Q., Deng, L., Ouyang, Q., Zhang, X. H.-F., & Zheng, J. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02148-4 · Cited by 244
“590,591 594 Targeted therapy represents a strategy to address drug resistance in cancer cells; however, it is also susceptible to drug resistance.”
The changing treatment landscape of EGFR-mutant non-small-cell lung cancer
Zhou, F., Guo, H., Xia, Y., Le, X., Tan, D. S. W., Ramalingam, S. S., & Zhou, C. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00971-2 · Cited by 182
“The prevailing theory suggests that tumour plasticity originates from drug-tolerant persister cells (DTPs) and cancer stem cells (CSCs) 190 , as discussed in the following section.”
InfluentialDoostmohammadi, A., Jooya, H., Ghorbanian, K., Gohari, S., & Dadashpour, M. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-024-01607-9 · Cited by 187
“It is the main challenge with monotherapies [8], which is attributed to up to 90% of cancer-associated deaths [27] and can be caused by various factors.”
BackgroundCancer stem cell mimicry for immune evasion and therapeutic resistance
Saw, P. E., Liu, Q., Wong, P., & Song, E. (2024) · Cell stem cell · doi:10.1016/j.stem.2024.06.003 · Cited by 182
Metadata
- Authors
- Shi, Z.-D., Pang, K., Wu, Z.-X., Dong, Y., Hao, L., Qin, J.-X., Wang, W., Chen, Z.-S., & Han, C.-H.
- Affiliations
- Xuzhou Medical College (CN)
- St. John's University (US)
- Southeast University (CN)
- Corresponding author
- Chen, Zhe-Sheng
- Venue
- Signal Transduction and Targeted Therapy
- Published
- 2023-03-11
- Volume
- 8
- Issue
- 1
- Pages
- 113-113
- ISSN
- 2059-3635 (ISSN-L)
- PMC
- PMC10008648
- OpenAlex
- W4323924126
- Cited by
- 256
- References
- 374
- Citations by year
- 2026: 85 · 2025: 92 · 2024: 59 · 2023: 20
- FWCI
- 8.58
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Signal Transduction and Targeted Therapy (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Natural Science Foundation of China (81774089, KC19075, BE2020758, 12271467, 82004110, BE2019637)
- Government of Jiangsu Province
- Topics
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
- Keywords
- tumor plasticity, targeted therapy resistance, acquired drug resistance, phenotypic switching, epithelial-mesenchymal transition, cancer stem cells, epigenetic modifications, transcription factors, tumor microenvironment, combination therapy
- MeSH terms
- Cell Plasticity, Humans, Neoplasms, Signal Transduction, Drug Resistance, Neoplasm, Epithelial-Mesenchymal Transition
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Tumor cell plasticity in targeted therapy-induced resistance: mechanisms and new strategies. https://app.cochat.ai/papers/10.1038/s41392-023-01383-x
- The paper
- Shi, Z.-D., Pang, K., Wu, Z.-X., Dong, Y., Hao, L., Qin, J.-X., Wang, W., Chen, Z.-S., & Han, C.-H. (2023). Tumor cell plasticity in targeted therapy-induced resistance: mechanisms and new strategies. Signal Transduction and Targeted Therapy. https://doi.org/10.1038/s41392-023-01383-x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.